The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Immunological studies have demonstrated a plethora of beneficial effects of dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets are incompletely understood and response markers are scarce. Here, we focus on the relation between nuclear factor (erythroid‐derived 2)‐like 2 (NRF 2) pathway induction under DMF therapy and the composition of the blood immune cell compartment and clinical efficacy in relapsing‐remitting multiple sclerosis (MS) patients. Methods: We explored effects of DMF on peripheral immune cell subsets by flow cytometric and transcriptional analysis of serial blood samples obtained from 43 MS patients during the first year of therapy. Results: Gene expression analysis proved activation of NRF 2 signaling under DMF therapy that was paralleled by a temporal expansion of FoxP3+ regulatory T cells, CD 56 bright natural killer cells, plasmacytoid dendritic cells, and a decrease in CD 8+ T cells, B cells, and type 1 myeloid dendritic cells. In a subgroup of 28 patients with completely available clinical data, individuals with higher levels of the NRF 2 target gene NAD(P)H quinone dehydrogenase 1 (NQO 1) 4–6 weeks after DMF therapy initiation were more likely to achieve no evidence of disease activity status 1 year later. The degree of NQO 1 induction further correlated with patient age. Interpretation: We demonstrate that positive effects of DMF on the clinical outcome are paralleled by induction of the antioxidant NRF 2 transcriptional pathway and a shift toward regulatory immune cell subsets in the periphery. Our data identify a role of the NRF 2 pathway as potential biomarker for DMF treatment in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 3×
“DMF reduces cytokine production,(10) downregulates the migratory activity of immune cells at the blood–brain barrier(11) and activates the nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcriptional pathway.(8,12) The antioxidant transcription factor NRF2 was described as critical regulator responsible for main…”
BackgroundResultSelf-citationZhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Identification of aldo-keto reductases as NRF2-target marker genes in human cells
Jung, K.-A., Choi, B.-H., Nam, C.-W., Song, M., Kim, S.-T., Lee, J. Y., & Kwak, M.-K. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.026 · Cited by 113
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
NRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
“…gene NQO1 in the blood of MS patients (Gopal et al., 2017; Hammer et al., 2018), and those patients who showed a significant increase in NQO1 expression after 4 to 6 weeks of treatment were more likely to achieve no evidence of disease activity status 1 year later (Hammer et al., 2018; Table 2).”
BackgroundAdvances and challenges in therapeutic targeting of NRF2
Dinkova-Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 266
Metadata
- Authors
- Hammer, A., Waschbisch, A., Kuhbandner, K., Bayas, A., Lee, D., Duscha, A., Haghikia, A., Gold, R., & Linker, R. A.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2018-04-16
- Volume
- 5
- Issue
- 6
- Pages
- 668-676
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2801318738
- Cited by
- 100
- References
- 6
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. https://app.cochat.ai/papers/10.1002/acn3.553
- The paper
- Hammer, A., Waschbisch, A., Kuhbandner, K., Bayas, A., Lee, D., Duscha, A., Haghikia, A., Gold, R., & Linker, R. A. (2018). The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.